Baxter International, Inc. Presents Efficacy And Safety Data On VIVIA Haemodialysis System At ERA-EDTA Congress

Published: Jun 03, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AMSTERDAM--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the presentation of clinical data supporting the safety and efficacy of the VIVIA haemodialysis (HD) system. Results from two studies conducted in a clinical setting showed acceptable clearance of uremic toxins and an overall safety profile similar to that associated with conventional HD devices. The VIVIA system, designed to deliver High Dose HD in the home, completed the CE marking process (market approval) in Europe, December 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news